Who is sponsoring NCT03715478?

NCT03715478 is sponsored by Canadian Myeloma Research Group.

What drugs are being tested in NCT03715478?

Interventions in NCT03715478: GSK2857916 with Pomalidomide and Dexamethasone.

What condition does NCT03715478 study?

NCT03715478 studies Relapsed and/or Refractory Multiple Myeloma.

Is NCT03715478 still recruiting?

NCT03715478 is currently active, enrolled. Last updated 8 January 2025.

Last reviewed 2025-01-08 · How we verify

NCT03715478

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex

Active, enrolled Phase 1, PHASE2 Last updated 8 January 2025

What this trial tests

Phase 1, PHASE2 trial testing GSK2857916 with Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma in 120 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

26 November 2018

Primary endpoint
1 June 2025

31 December 2026

Quick facts

Lead sponsor	Canadian Myeloma Research Group
Phase	Phase 1, PHASE2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	26 November 2018
Primary completion	1 June 2025
Estimated completion	31 December 2026
Sites	9 locations across Canada

Drugs / interventions tested

GSK2857916 with Pomalidomide and Dexamethasone — full drug profile →

Conditions studied

Relapsed and/or Refractory Multiple Myeloma — all drugs for Relapsed and/or Refractory Multiple Myeloma →

Sponsor

Canadian Myeloma Research Group

Who can join

18 and older, any sex, with Relapsed and/or Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1/2, multi-centre, single-arm, open-label, dose-escalation study that will evaluate the safety and efficacy of IV GSK2857916 in combination with PO pomalidomide and low-dose PO dexamethasone in subjects with relapsed and/or refractory MM.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Antibodies to watch in 2020.
Kaplon H, Muralidharan M, Schneider Z, Reichert JM. · · 2020 · cited 332× · PMID 31847708 · DOI 10.1080/19420862.2019.1703531
BCMA-targeted immunotherapy for multiple myeloma.
Yu B, Jiang T, Liu D. · · 2020 · cited 165× · PMID 32943087 · DOI 10.1186/s13045-020-00962-7
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
Lonial S, Nooka AK, Thulasi P, Badros AZ, et al · · 2021 · cited 63× · PMID 34039952 · DOI 10.1038/s41408-021-00494-4
Emerging agents and regimens for multiple myeloma.
Yang Y, Li Y, Gu H, Dong M, et al · · 2020 · cited 57× · PMID 33168044 · DOI 10.1186/s13045-020-00980-5
Multiple Myeloma Therapy: Emerging Trends and Challenges.
Dima D, Jiang D, Singh DJ, Hasipek M, et al · · 2022 · cited 51× · PMID 36077618 · DOI 10.3390/cancers14174082
Targeted Therapy With Immunoconjugates for Multiple Myeloma.
Bruins WSC, Zweegman S, Mutis T, van de Donk NWCJ. · · 2020 · cited 42× · PMID 32636838 · DOI 10.3389/fimmu.2020.01155
BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.
Cho SF, Lin L, Xing L, Li Y, et al · · 2020 · cited 42× · PMID 32516895 · DOI 10.3390/cancers12061473
Bispecifics, trispecifics, and other novel immune treatments in myeloma.
Lancman G, Richter J, Chari A. · · 2020 · cited 41× · PMID 33275733 · DOI 10.1182/hematology.2020000110

Verify or expand the search:

Other recruiting trials for Relapsed and/or Refractory Multiple Myeloma

Currently open trials in the same condition.

NCT06153251 — A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT06182696 — OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM · Phase 1, PHASE2 · recruiting

Other Canadian Myeloma Research Group trials

Trials by the same sponsor.

NCT04258683 — A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (Cy · Phase 2 · withdrawn
NCT03697629 — A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma · Phase 2 · completed
NCT03215524 — A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03715478 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Canadian Myeloma Research Group
Last refreshed: 8 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03715478.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing